Development of a remote IoT laboratory for cyber physical systems

A remote Internet of Things (IoT) laboratory has been developed for use in teaching and research of cyber physical systems. The laboratory is configured such that users interact via the web to control and collect data from connected devices. The concept and technology of the remote IoT lab is successfully demonstrated in two applications. First the laboratory is configured for UTChattSat, a ground model small-satellite system (CubeSat) designed to enhance K-12 learning in the space sciences. The system utilizes real-time communication and web-based user control to create a distributed multi-user interface. Second, the laboratory is configured for a distributed sensor network with a single-user interface. The interconnected, real time, and smart system with embedded sensors and processors is used to provide data for assessment of current building energy models. Finally, challenges posed by interconnected and reconfigurable systems and the implementable future works are discussed

Pediatric Oral Medications Screening Study

Objective: Difficulties with swallowing medicine is a common barrier in oral medication administration and compliance. Given the importance of early transition to oral medication to reduce treatment-related complications, our goal is to identify children with oral medication swallowing difficulties early in their hospital stay in order to provide them with timely inpatient interventions. By teaching children how to swallow medicines, we hope to optimize their quality of care and eventually decrease healthcare costs associated with intravenous medications. Methods: We screened 34 general inpatient pediatric patients on their oral medication taking abilities from April 2014 to June 2014. Patients who did not meet their age goals were referred to pediatric recreational therapists for medication swallowing interventions (POMS+). Children were then post-screened to assess improvement after the POMS+ intervention. A separate retrospective chart review was done to assess the prevalence of PICC line placements and the average length of stay for general inpatient pediatric patients at UNC Children's Hospital from January 2010 to December 2013. Results: Approximately 18% (6 out of 34) of our study population did not pass the oral medications screening test. Of the patients who did not pass our screen, 50% (3 out of 6) successfully completed our POMS+ intervention and showed noteworthy improvements in their medication taking abilities. Children who did not pass the screen were significantly different than children who did pass the screen on the following measures: parent-reported anxiety rating, child-reported rating on how taking medicine by mouth makes them feel, and proportion of children with previous or current Psychiatric/Psychological services. Conclusions: Screening pediatric patients in the hospital about their ability to swallow oral medications is an effective way to identify children who may benefit from medication swallowing interventions and to facilitate early transition to oral medications. As a result, this screening protocol can improve the quality of care we provide our pediatric patients and can decrease healthcare costs associated with intravenous medication.Master of Public Healt

Piperacillin-tazobactam induced hypokalaemia

Electrolytes imbalance has been reported with the use of several antimicrobials in clinical scenarios. Piperacillin/tazobactam is a commonly used antibiotic with tolerable side effects and broad antimicrobial activity in general practice. Herein we report a case of a 27 year old male presented with Road Traffic Accident with depressed frontal bone fracture, fracture humerus and fracture of great toe complicated with Ventilator associated Pneumonia (VAP) who developed hypokalemia secondary to intravenous piperacillin-tazobactam. Upon withdrawal of the drug, serum potassium normalized in 2 days. There were no other underlying renal or hepatic illness and other causes of hypokalemia. Hypokalemia is a serious adverse effect of piperacillin-tazobactam and should be suspected while treating patients with this drug in clinical practice especially in Intensive Care Units (ICU). We concluded this causality as probable/likely category according to WHO-UMC Causality Categories

Can Physician Champions Improve Kangaroo Care? Trends over 5 Years in Rural Western India

Introduction: In 2013, approximately 2.8 million children worldwide died within the neonatal period. India is at the epicenter of this tragedy, accounting for one-third of all neonatal mortalities. Prematurity and/or with low birth weight are the leading cause of neonatal mortality and India has the highest number of neonates born preterm and weighing less than 2,500 grams worldwide. It is estimated that Kangaroo Care can avert up to 48% of all neonatal deaths among premature babies by 2025. However, the promise of Kangaroo Care as a low-cost, safe, and efficacious intervention to reduce neonatal mortality in India has not been realized due to suboptimal implementation. Physician champions can improve Kangaroo Care implementation, but the magnitude of their impact is unknown. Methods: A retrospective cohort study of 648 infants identified using clinical data from a NICU located in rural western India. Physicians who led Kangaroo Care training sessions with neonates and coached peer healthcare professionals were considered champions. Two Kangaroo Care champions were on staff full-time from January 2010 through June 2011, part-time from July 2011 through June 2012, and absent thereafter. We examined the effect of the withdrawal of physician champions on overall use using logistic regression, time to initiation using competing risk cox regression, and intensity using linear regression models of the two main components of Kangaroo Care, skin-to-skin care and breastfeeding, separately. Findings: In comparison to when Kangaroo Care champions were present, their absence was associated with a 45% decrease in the odds of receiving skin-to-skin care (95% CI): 64% to 17%), 38% decrease in the rate of initiation of skin-to-skin care (95% CI: 53% to 82%), and on average, 1.47 less hours of skin-to-skin care (95% CI: -2.07 to -0.86). Breastfeeding practices were similar across different champion environments. Interpretation: Withdrawal of Kangaroo Care champions from neonatal intensive care unit in rural western India is associated with diminished administration, delayed initiation, and shorter duration of skin-to-skin care, but did not impact breastfeeding practices. Training healthcare workers and community stakeholders to become champions could help in scaling up and maintaining Kangaroo Care practices. Funding: This research was supported by TL1-TR001454 (to A.S.) from National Center for Advancing Translational Sciences, and P60-MD006912-05 (to J.A.) from National Institute on Minority Health and Disparities. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH

Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.

INTRODUCTION The global target for 2020 is that ≥90% of people living with HIV (PLHIV) receiving antiretroviral therapy (ART) will achieve viral load suppression (VLS). We examined VLS and its determinants among adults receiving ART for at least four months. METHODS We analysed data from the population-based HIV impact assessment (PHIA) surveys in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017). PHIA surveys are nationally representative, cross-sectional household surveys. Data collection included structured interviews, home-based HIV testing and laboratory testing. Blood samples from PLHIV were analysed for HIV RNA, CD4 counts and recent exposure to antiretroviral drugs (ARVs). We calculated representative estimates for the prevalence of VLS (viral load <1000 copies/mL), nonsuppressed viral load (NVL; viral load ≥1000 copies/mL), virologic failure (VF; ARVs present and viral load ≥1000 copies/mL), interrupted ART (ARVs absent and viral load ≥1000 copies/mL) and rates of switching to second-line ART (protease inhibitors present) among PLHIV aged 15 to 59 years who participated in the PHIA surveys in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe, initiated ART at least four months before the survey and were receiving ART at the time of the survey (according to self-report or ARV testing). We calculated odds ratios and incidence rate ratios for factors associated with NVL, VF, interrupted ART, and switching to second-line ART. RESULTS We included 9200 adults receiving ART of whom 88.8% had VLS and 11.2% had NVL including 8.2% who experienced VF and 3.0% who interrupted ART. Younger age, male sex, less education, suboptimal adherence, receiving nevirapine, HIV non-disclosure, never having married and residing in Zimbabwe, Lesotho or Zambia were associated with higher odds of NVL. Among people with NVL, marriage, female sex, shorter ART duration, higher CD4 count and alcohol use were associated with lower odds for VF and higher odds for interrupted ART. Many people with VF (44.8%) had CD4 counts <200 cells/µL, but few (0.31% per year) switched to second-line ART. CONCLUSIONS Countries are approaching global VLS targets for adults. Treatment support, in particular for younger adults, and people with higher CD4 counts, and switching of people to protease inhibitor- or integrase inhibitor-based regimens may further reduce NVL prevalence

Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis

BACKGROUND. Antigen-specific regulation of autoimmune disease is a major goal. In seropositive rheumatoid arthritis (RA), T cell help to autoreactive B cells matures the citrullinated (Cit) antigen-specific immune response, generating RA-specific V domain glycosylated anti-Cit protein antibodies (ACPA VDG) before arthritis onset. Low or escalating antigen administration under “sub-immunogenic” conditions favors tolerance. We explored safety, pharmacokinetics, and immunological and clinical effects of s.c. DEN-181, comprising liposomes encapsulating self-peptide collagen II259-273 (CII) and NF-κB inhibitor 1,25-dihydroxycholecalciferol. METHODS. A double-blind, placebo-controlled, exploratory, single-ascending-dose, phase I trial assessed the impact of low, medium, and high DEN-181 doses on peripheral blood CII-specific and bystander Cit64vimentin59-71–specific (Cit-Vim–specific) autoreactive T cell responses, cytokines, and ACPA in 17 HLA-DRB1*04:01+ or *01:01+ ACPA+ RA patients on methotrexate. RESULTS. DEN-181 was well tolerated. Relative to placebo and normalized to baseline values, Cit-Vim–specific T cells decreased in patients administered medium and high doses of DEN-181. Relative to placebo, percentage of CII-specific programmed cell death 1+ T cells increased within 28 days of DEN-181. Exploratory analysis in DEN-181–treated patients suggested improved RA disease activity was associated with expansion of CII-specific and Cit-Vim–specific T cells; reduction in ACPA VDG, memory B cells, and inflammatory myeloid populations; and enrichment in CCR7+ and naive T cells. Single-cell sequencing identified T cell transcripts associated with tolerogenic TCR signaling and exhaustion after low or medium doses of DEN-181. CONCLUSION. The safety and immunomodulatory activity of low/medium DEN-181 doses provide rationale to further assess antigen-specific immunomodulatory therapy in ACPA+ RA